摘要
肝癌是常见且恶性程度高的癌症之一,其中90%为肝细胞癌,对人类健康构成严重威胁。由于早期肝癌无特异性表现,大部分确诊时已处于中晚期,错过了最佳的根治治疗时机。关于中晚期原发性肝细胞癌治疗的探索从未停歇。近年来,经动脉化疗栓塞术(transarterial chemoembolization,TACE)已被纳入原发性肝细胞癌的标准治疗方案中。随着多学科综合治疗的推进,各种减轻肝细胞癌负荷的治疗方案已经广泛应用于临床中,如肝动脉灌注化疗(hepatic artery infusion chemotherapy,HAIC)、靶向治疗和免疫治疗等与TACE的联用,提高了肝癌患者的总生存率。本文重点介绍原发性肝细胞癌研究中,TACE与其他疗法的联用在降低肿瘤负荷、提高患者生存率方面的进展,并总结联合治疗中需要进行更深入研究的关键问题。
Liver cancer is a prevalent and highly malignant cancer worldwide,with 90%of cases being hepatocellular carcinoma,presenting a significant risk to human health.As early-stage liver cancer often lacks specific manifestations,most patients with liver cancer are already in the middle and late stage of the disease when liver cancer is diagnosed,thus,missing the opportunity for optimal radical treatment.However,the exploration of the treatment for middle and advanced primary hepatocellular carcinoma has never ceased.In recent years,transarterial chemoembolization(TACE)has been included in the standard treatment regimens for primary hepatocellular carcinoma.With the advancement of multidisciplinary comprehensive treatment,various treatment options to reduce the burden of liver cancer lesion with satisfactory therapeutic results have been reported and have been widely used in clinical practice,e.g.hepatic artery infusion chemotherapy(HAIC),targeted therapy,and immunotherapy in combination with TACE,which have significantly improved the overall survival of patients with liver cancer.This paper aims to make a comprehensive review about the latest progress of combination use of TACE and other therapies in reducing tumor burden and improving patient survival in the treatment of primary hepatocellular carcinoma,and to summarize the key issues in combination therapy that require more in-depth research.
作者
肖正芳
郑游冰
邓飞燕
郑思茜
孙宏伟
刘妍妍
陆骊工
XIAO Zhengfang;ZHENG Youbing;DENG Feiyan;ZHENG Siqian;SUN Hongwei;LIU Yanyan;LU Ligong(Affiliated Zhuhai Hospital of Jinan University(Zhuhai Municipal People's Hospital),Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment,Zhuhai,Guangdong Province 519000,China)
出处
《介入放射学杂志》
CSCD
北大核心
2024年第6期688-692,共5页
Journal of Interventional Radiology
基金
多模态可视化筛选肝癌介入术后免疫治疗获益人群的研究(82230067)
广东省肿瘤介入诊治研究重点实验室(2021年度)(2021B1212040004)。
关键词
肝细胞癌
肝动脉化疗栓塞
灌注化疗
靶向治疗
免疫治疗
联合治疗
hepatocellular carcinoma
hepatic arterial chemoembolization
perfusion chemotherapy
targeted therapy
immunotherapy
combination therapy
